RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia

References

• Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011;4:36.
   PubMed Web of Science ®Google Scholar
• Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129:2070–2082.
   PubMed Web of Science ®Google Scholar
• Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166–175.
   PubMed Web of Science ®Google Scholar
• Yokota A, Huo L, Lan F, et al. The clinical, molecular, and mechanistic basis of RUNX1 mutations identified in hematological malignancies. Mol Cells. 2020;43:145–152.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30:2160–2168.
   PubMed Web of Science ®Google Scholar
• Greif PA, Konstandin NP, Metzeler KH, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012;97:1909–1915.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29:1364–1372.
   PubMed Web of Science ®Google Scholar
• Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352–5361.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117:2348–2357.
   PubMed Web of Science ®Google Scholar
• Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012;30:3109–3118.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Khan M, Cortes J, Kadia T, et al. Clinical outcomes and Co-occurring mutations in patients with RUNX1-Mutated acute myeloid leukemia. Int J Mol Sci. 2017;18:1618.
   PubMed Web of Science ®Google Scholar
• Quesada AE, Montalban-Bravo G, Luthra R, et al. Clinico-pathologic characteristics and outcomes of the world health organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020;33:1678–1689.
   PubMed Web of Science ®Google Scholar
• Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487.
   PubMed Web of Science ®Google Scholar
• Asada S, Kitamura T. Clonal hematopoiesis and associated diseases: a review of recent findings. Cancer Sci. 2021;112:3962–3971.
   PubMed Web of Science ®Google Scholar
• Stengel A, Baer C, Walter W, et al. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv. 2021;5:4426–4434.
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199.
   PubMed Web of Science ®Google Scholar
• Heuser M, Heida B, Büttner K, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5:2294–2304.
   PubMed Web of Science ®Google Scholar
• Yao H, Huo L, Ping N, et al. Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2022;196(2):441–444.
   PubMed Web of Science ®Google Scholar
• Liu SB, Dong HJ, Bao XB, et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. Haematologica. 2019;104:e9–e12.
   PubMed Web of Science ®Google Scholar
• Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL). Zhonghua Xue Ye Xue Za Zhi. 2017;38:177–182.
   PubMedGoogle Scholar
• Ben-Ami O, Friedman D, Leshkowitz D, et al. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep. 2013;4:1131–1143.
   PubMed Web of Science ®Google Scholar
• Nagata T, Werner MH. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain. J Mol Biol. 2001;308:191–203.
   PubMed Web of Science ®Google Scholar
• Yan M, Ahn EY, Hiebert SW, et al. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood. 2009;113(4):883–886.
   PubMed Web of Science ®Google Scholar
• Braekeleer D, Douet-Guilbert E, Morel N, et al. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol. 2011;7(1):77–91.
   PubMed Web of Science ®Google Scholar
• Stengel A, Kern W, Meggendorfer M, et al. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. Leukemia. 2018;32(2):295–302.
   PubMed Web of Science ®Google Scholar
• Asada S, Fujino T, Goyama S, et al. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76(13):2511–2523.
   PubMed Web of Science ®Google Scholar
• Izzo F, Lee SC, Poran A, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020;52(4):378–387.
   PubMed Web of Science ®Google Scholar
• van Zeventer IA, de Graaf AO, Wouters H, et al. Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. Blood. 2020;135(14):1161–1170.
   PubMed Web of Science ®Google Scholar
• Chen SF, Wang TZ, Jiang SH, et al. Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations. Zhonghua Xue Ye Xue Za Zhi. 2018;39:983–988.
   PubMedGoogle Scholar